Genomics and Bioinformatics in Biological Discovery and Pharmaceutical Development

2020 ◽  
pp. 105-142
Author(s):  
Wendell Jones
Keyword(s):  
Pharmaceutical Development ◽  
Biological Discovery

Total Synthesis of Axially-Chiral Cannabinols: A New Platform for Cannabinoid-Based Drug Discovery

2019 ◽  
Author(s):  
Primali Navaratne ◽  
Jenny Wilkerson ◽  
Kavindri Ranasinghe ◽  
Evgeniya Semenova ◽  
Lance McMahon ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Total Synthesis ◽  
Ground State ◽  
Chemical Space ◽  
Modern Medicine ◽  
The Novel ◽  
Pharmaceutical Development ◽  
Bioactive Component ◽  
Axially Chiral ◽  
New Directions

<div> <div> <div> <p>Phytocannabinoids, molecules isolated from cannabis, are gaining attention as promising leads in modern medicine, including pain management. Considering the urgent need for combating the opioid crisis, new directions for the design of cannabinoid-inspired analgesics are of immediate interest. In this regard, we have hypothesized that axially-chiral-cannabinols (ax-CBNs), unnatural (and unknown) isomers of cannabinol (CBN) may be valuable scaffolds for cannabinoid-inspired drug discovery. There are multiple reasons for thinking this: (a) ax-CBNs would have ground-state three-dimensionality akin to THC, a key bioactive component of cannabis, (b) ax-CBNs at their core structure are biaryl molecules, generally attractive platforms for pharmaceutical development due to their ease of functionalization and stability, and (c) atropisomerism with respect to phytocannabinoids is unexplored “chemical space.” Herein we report a scalable total synthesis of ax-CBNs, examine physical properties experimentally and computationally, and provide preliminary behavioral and analgesic analysis of the novel scaffolds. </p> </div> </div> </div>

scholarly journals BRAZILIANTRADITIONAL MEDICINE: HISTORICAL BASIS, FEATURES AND POTENTIALITIES FOR PHARMACEUTICAL DEVELOPMENT

2020 ◽  
Author(s):  
Hlupheka Chabalala ◽  
Motlalepula Gilbert Matsabisa ◽  
Nceba Gqaleni ◽  
Giovanni Silvano ◽  
Fernão Castro Braga ◽  
...  
Keyword(s):  
Pharmaceutical Development ◽  
Historical Basis

scholarly journals Molecular Phenomic Approaches to Deconvolving the Systemic Effects of SARS-CoV-2 Infection and Post-acute COVID-19 Syndrome

Phenomics ◽  
2021 ◽  
Author(s):  
Jeremy K. Nicholson
Keyword(s):  
Molecular Level ◽  
Organ Damage ◽  
Zoonotic Diseases ◽  
Mitigation Strategies ◽  
Health Consequence ◽  
Metabolic Phenotyping ◽  
Persistent Symptoms ◽  
Biological Discovery ◽  
New Biomarkers

AbstractSARS COV-2 infection causes acute and frequently severe respiratory disease with associated multi-organ damage and systemic disturbances in many biochemical pathways. Metabolic phenotyping provides deep insights into the complex immunopathological problems that drive the resulting COVID-19 disease and is also a source of novel metrics for assessing patient recovery. A multiplatform metabolic phenotyping approach to studying the pathology and systemic metabolic sequelae of COVID-19 is considered here, together with a framework for assessing post-acute COVID-19 Syndrome (PACS) that is a major long-term health consequence for many patients. The sudden emergence of the disease presents a biological discovery challenge as we try to understand the pathological mechanisms of the disease and develop effective mitigation strategies. This requires technologies to measure objectively the extent and sub-phenotypes of the disease at the molecular level. Spectroscopic methods can reveal metabolic sub-phenotypes and new biomarkers that can be monitored during the acute disease phase and beyond. This approach is scalable and translatable to other pathologies and provides as an exemplar strategy for the investigation of other emergent zoonotic diseases with complex immunological drivers, multi-system involvements and diverse persistent symptoms.

scholarly journals Orphan Designation and Cisplatin/Hyaluronan Complex in an Intracavitary Film for Malignant Mesothelioma

Pharmaceutics ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 362
Author(s):  
Sabrina Banella ◽  
Eride Quarta ◽  
Paolo Colombo ◽  
Fabio Sonvico ◽  
Antonella Pagnoni ◽  
...  
Keyword(s):  
Sodium Hyaluronate ◽  
Chloride Ions ◽  
Complete Resection ◽  
Size Exclusion ◽  
European Medicines Agency ◽  
Reverse Phase Hplc ◽  
Reverse Phase ◽  
Pharmaceutical Development ◽  
Film Forming ◽  
Exclusion Chromatography

Pleural mesothelioma is a lung diffuse tumor, whose complete resection is unlikely. Consequently, metastases reappear where the primary tumor was removed. This paper illustrates the orphan medicine designation procedure of an intracavitary cisplatin film and related pharmaceutical development aspects requested by the European Medicines Agency (EMA) in its Scientific Advice. Since cisplatin pharmacokinetics from the implanted film in sheep resulted substantially modified compared to intravenous administration, the formation of a cisplatin/hyaluronan complex had been hypothesized. Here, the interaction between sodium hyaluronate (NaHA) and cisplatin (CisPt) was demonstrated. Size exclusion chromatography qualitatively evidenced the complex in the film-forming mixture, only showing the NaHA peak. Atomic absorption spectroscopy of the corresponding fraction revealed platinum, confirming the interaction. Reverse phase HPLC quantified about 5% free cisplatin in the film-forming mixture, indirectly meaning that 95% was complexed. Finally, a study of CisPt release from the film assessed how CisPt/NaHA complex affected drug availability. In water, a medium without chloride ions, there was no release and the film remained intact for 48 h and longer, whereas the placebo film dissolved in 15 min. In 0.9% NaCl medium, the film became more soluble, dissolving within 3–4 h. However, cisplatin release was still controlled by the existing complex in solution until chloride ions displaced it. While the film modified its dissolution with aging, CisPt release remained unaffected (90% released in 48 h).

scholarly journals History of Pharmaceutical Development in Nepal

2018 ◽  
Vol 3 (1) ◽  
pp. 86-93
Author(s):  
Dharma Prasad Khanal
Keyword(s):  
Private Sector ◽  
Hospital Pharmacy ◽  
Historical Event ◽  
Ayurvedic Medicine ◽  
Allopathic Medicine ◽  
Institute Of Medicine ◽  
Pharmaceutical Development ◽  
Mission Hospital ◽  
History Of ◽  
Pharmaceutical Education

The historical event of the development of pharmacy was started during ancient Lichchhavi ruler Amshu Berma date back to 605-620 AD when a Ayurvedic hospital was established. In 1641-1674 AD, King Pratap Malla started ayurvedic medicine production unit in the royal place. Modern allopathic medicines were introduced in Nepal in 1816 AD after Suguali Treaty and establishment of British residency in Nepal. Allopathic medicine manufacturing was started in 1969 in private sector and a government undertaking Royal Drug Limited was established in 1972.  Department of Drug Administration (DDA), a drug regulating Agency of the country was established according to the Drug Act in 1979. The pharmaceutical education was started in Nepal with the commencement of the Proficiency Certificate Level, a two and half year program (Intermediate in Pharmacy that is similar to Diploma of Pharmacy) at the Institute of Medicine, Tribhuban University in 1972. Santabhavan Hospital (present patan Hospital that was established in 1956) is pioneer to start hospital Pharmacy service in Nepal followed by Tansen Mission hospital Palpa that was started operation in 1959.Journal of Manmohan Memorial Institute of Health SciencesVol. 3, No. 1, 2017, page: 86-93 

Pharmaceutical Development of a Parenteral Formulation of Conivaptan Hydrochloride

2013 ◽  
Vol 67 (4) ◽  
pp. 336-353 ◽  
Author(s):  
K. Ban ◽  
R. Sonohara ◽  
M. Yoshida ◽  
K. Sako ◽  
S. Uchida ◽  
...  
Keyword(s):  
Parenteral Formulation ◽  
Pharmaceutical Development
Sign in / Sign up

Export Citation Format

Share Document